Director at Neurocrine (NASDAQ: NBIX) receives 2,567 RSUs as award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Sharp Shalini reported acquisition or exercise transactions in this Form 4 filing.

Neurocrine Biosciences director Shalini Sharp received a grant of 2,567 restricted stock units (RSUs). Each RSU represents one share of common stock upon vesting, and the entire award will vest on May 27, 2027. This is a stock-based compensation grant, not an open-market share purchase or sale, and leaves her with 2,567 RSUs reported as directly held.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sharp Shalini

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restriced Stock Unit	2,567	$0.00	--

Holdings After Transaction: Restriced Stock Unit — 2,567 shares (Direct, null)

Footnotes (1)

Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. The RSUs will vest in full on May 27, 2027.

Key Figures

RSUs granted: 2,567 units Grant price per RSU: $0.00 Underlying common shares: 2,567 shares +2 more

5 metrics

RSUs granted 2,567 units Restricted Stock Unit award to director on May 27, 2026

Grant price per RSU $0.00 Equity compensation, not open-market purchase

Underlying common shares 2,567 shares Each RSU equals one share of common stock upon vesting

Post-transaction RSU holdings 2,567 units Total restricted stock units directly held after grant

Vesting date May 27, 2027 RSUs vest in full on this date

Key Terms

Restricted Stock Unit, RSU, common stock, vesting

4 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share..."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

RSU financial

"Each Restricted Stock Unit ("RSU") represents the right to receive one share..."

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

common stock financial

"represents the right to receive one share of the Issuer's common stock upon vesting."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"The RSUs will vest in full on May 27, 2027."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 05/29/2026 - 06:03 PM Accepted by SEC EDGAR 05/29/2026 - 06:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sharp Shalini

(Last)

(First)

(Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restriced Stock Unit⁽¹⁾	$0	05/27/2026		A		2,567		⁽²⁾	⁽²⁾	Common Stock	2,567	$0	2,567	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

2. The RSUs will vest in full on May 27, 2027.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	05/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did NBIX director Shalini Sharp report on this Form 4?

Shalini Sharp reported receiving a grant of 2,567 restricted stock units in Neurocrine Biosciences. These RSUs are a form of equity compensation and do not involve an open-market purchase or sale of the company’s common stock.

How many Neurocrine Biosciences (NBIX) RSUs did the director receive?

The director received 2,567 restricted stock units tied to Neurocrine Biosciences common stock. Each RSU represents the right to receive one share of common stock when it vests, aligning director compensation with shareholder interests over time.

When do the newly granted NBIX restricted stock units vest?

The 2,567 restricted stock units will vest in full on May 27, 2027. Once vested, each RSU converts into one share of Neurocrine Biosciences common stock, subject to any applicable company policies or restrictions on transfer or sale.

Is this NBIX Form 4 transaction a stock purchase or sale?

No, this Form 4 reflects a grant of restricted stock units, not a market trade. The RSUs were awarded as compensation at a stated price of $0.00 per unit and will convert into common shares only upon vesting in 2027.

How many Neurocrine Biosciences shares or units does the director hold after this grant?

Following this transaction, the Form 4 shows the director holding 2,567 restricted stock units directly. These units represent future rights to receive an equal number of Neurocrine Biosciences common shares when the award vests on May 27, 2027.